Loading
A phase 1/2 trial of BA3071, Nivolumab, Pembrolizumab in melanoma, run by BioAtla, Inc., active and no longer recruiting.
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05180799 by BioAtla, Inc., with 320 participants planned, started 2022-08-03 and due to reach its primary completion in 2025-03-19. Interventions recorded: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta). Conditions listed: NSCLC, Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Pembrolizumab.
Shares Pemetrexed, Melanoma, Pembrolizumab.
Shares Pemetrexed, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/